BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

455 related articles for article (PubMed ID: 33728111)

  • 1. Antibiotic-Eluting Envelopes to Prevent Cardiac-Implantable Electronic Device Infection: Past, Present, and Future.
    Xiang K; Catanzaro JN; Elayi C; Esquer Garrigos Z; Sohail MR
    Cureus; 2021 Feb; 13(2):e13088. PubMed ID: 33728111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk profiles and outcomes of patients receiving antibacterial cardiovascular implantable electronic device envelopes: A retrospective analysis.
    Woodard DA; Kim G; Nilsson KR
    World J Cardiol; 2022 Mar; 14(3):177-186. PubMed ID: 35432770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk Profiles and Outcomes of Patients Receiving Cardiovascular Implantable Electronic Devices With and Without Antibacterial Envelopes.
    Woodard DA; Kim G; Nilsson KR
    Cureus; 2022 May; 14(5):e24739. PubMed ID: 35686253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibacterial Envelope Is Associated With Low Infection Rates After Implantable Cardioverter-Defibrillator and Cardiac Resynchronization Therapy Device Replacement: Results of the Citadel and Centurion Studies.
    Henrikson CA; Sohail MR; Acosta H; Johnson EE; Rosenthal L; Pachulski R; Dan D; Paladino W; Khairallah FS; Gleed K; Hanna I; Cheng A; Lexcen DR; Simons GR
    JACC Clin Electrophysiol; 2017 Oct; 3(10):1158-1167. PubMed ID: 29759500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibacterial Envelope to Prevent Cardiac Implantable Device Infection.
    Tarakji KG; Mittal S; Kennergren C; Corey R; Poole JE; Schloss E; Gallastegui J; Pickett RA; Evonich R; Philippon F; McComb JM; Roark SF; Sorrentino D; Sholevar D; Cronin E; Berman B; Riggio D; Biffi M; Khan H; Silver MT; Collier J; Eldadah Z; Wright DJ; Lande JD; Lexcen DR; Cheng A; Wilkoff BL;
    N Engl J Med; 2019 May; 380(20):1895-1905. PubMed ID: 30883056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences between cardiac implantable electronic device envelopes evaluated in an animal model.
    Ip JE; Xu L; Lerman BB
    J Cardiovasc Electrophysiol; 2021 May; 32(5):1346-1354. PubMed ID: 33010088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of a Bio-Absorbable Antibacterial Envelope to Prevent Cardiac Implantable Electronic Device Infections in High-Risk Subjects.
    Kolek MJ; Patel NJ; Clair WK; Whalen SP; Rottman JN; Kanagasundram A; Shen ST; Saavedra PJ; Estrada JC; Abraham RL; Ellis CR
    J Cardiovasc Electrophysiol; 2015 Oct; 26(10):1111-6. PubMed ID: 26222980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient Profiles in the Utilization of the CanGaroo® Envelope.
    Nayak H; Beaser AD; Aziz ZA
    Cureus; 2021 Jan; 13(1):e12702. PubMed ID: 33604224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced Antimicrobial Effects of Decellularized Extracellular Matrix (CorMatrix) with Added Vancomycin and Gentamicin for Device Implant Protection.
    Deering TF; Chang C; Snyder C; Natarajan SK; Matheny R
    Pacing Clin Electrophysiol; 2017 Jun; 40(6):615-623. PubMed ID: 28240419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Do barrier dressings reduce cardiac implantable device infection: Protocol for a randomized controlled trial (BARRIER-PROTECT).
    Aydin A; Golian M; Klein A; Redpath C; Davis DR; Ramirez DF; Nair GM; Green M; Sadek M; Nery PB; Hansom SP; Corrales-Medina V; Wells GA; Birnie DH
    Heliyon; 2023 Dec; 9(12):e22229. PubMed ID: 38046145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of envelopes on cardiac implantable electronic device pocket healing: A head-to-head preclinical evaluation.
    Virmani R; Philippon F; Mittal S; Finn A; Kudlik D; Kirchhof N; Lexcen D; Kassotis J
    Heart Rhythm; 2024 Mar; ():. PubMed ID: 38555971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of Cardiovascular Implantable Electronic Devices Infections in High-Risk Patients.
    Kennergren C
    Arrhythm Electrophysiol Rev; 2015 May; 4(1):53-7. PubMed ID: 26835101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strategies to prevent infections associated with cardiovascular implantable electronic devices.
    Palraj BR; Farid S; Sohail MR
    Expert Rev Med Devices; 2017 May; 14(5):371-381. PubMed ID: 28434261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibiotic-Eluting Envelopes for the Prevention of Cardiac Implantable Electronic Device Infections: Rationale, Efficacy, and Cost-Effectiveness.
    Traykov V; Blomström-Lundqvist C
    Front Cardiovasc Med; 2022; 9():855233. PubMed ID: 35419433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of bacteremia in patients living with cardiovascular implantable electronic devices.
    DeSimone DC; Sohail MR
    Heart Rhythm; 2016 Nov; 13(11):2247-2252. PubMed ID: 27546815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized Trial of Stand-Alone Use of the Antimicrobial Envelope in High-Risk Cardiac Device Patients.
    Ellis CR; Greenspon AJ; Andriulli JA; Gould PA; Carillo RG; Kolek MJ; Donegan R; Amaral AP; Mittal S
    Circ Arrhythm Electrophysiol; 2023 May; 16(5):e011740. PubMed ID: 36960716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Physician antibiotic hydration preferences for biologic antibacterial envelopes during cardiac implantable device procedures.
    Deering TF; Catanzaro JN; Woodard DA
    Front Cardiovasc Med; 2022; 9():1006091. PubMed ID: 36620632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of an antibacterial envelope is associated with reduced cardiac implantable electronic device infections in high-risk patients.
    Kolek MJ; Dresen WF; Wells QS; Ellis CR
    Pacing Clin Electrophysiol; 2013 Mar; 36(3):354-61. PubMed ID: 23252988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical evaluation of efficacy and pharmacokinetics of gentamicin containing extracellular-matrix envelope.
    Sohail MR; Esquer Garrigos Z; Elayi CS; Xiang K; Catanzaro JN
    Pacing Clin Electrophysiol; 2020 Mar; 43(3):341-349. PubMed ID: 32067241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The World-wide Randomized Antibiotic Envelope Infection Prevention (WRAP-IT) trial: Long-term follow-up.
    Mittal S; Wilkoff BL; Kennergren C; Poole JE; Corey R; Bracke FA; Curnis A; Addo K; Martinez-Arraras J; Issa ZF; Redpath C; Moubarak J; Khelae SK; Boersma LVA; Korantzopoulos P; Krueger J; Lande JD; Morss GM; Seshadri S; Tarakji KG
    Heart Rhythm; 2020 Jul; 17(7):1115-1122. PubMed ID: 32087357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.